DEFINITY

How to Use DEFINITY®: System Optimization



Because every patient poses unique imaging challenges...

Optimize your DEFINITY® contrast images1,2


Leading societies advocate ultrasound contrast when image quality is suboptimal1,3:

American Society of Echocardiography (ASE) Consensus Statement1:

"Despite optimization of transducer frequency, sector width, and focus position, image quality can stay suboptimal in these patients unless [an ultrasound] contrast agent is used."

 

The Intersocietal Accreditation Commission for Echocardiography Laboratories (IAC) states...3

  • Poor endocardial border definition is defined as the inability to detect 2 or more contiguous segments in any 3 of the apical views

  • Contrast should be used in the presence of poor endocardial border definition to quantify chamber dimensions and volumes, and to assess regional wall motion

Loading the player ...

Because every patient poses unique imaging challenges, it is important to adjust the controls on your ultrasound system to achieve optimal contrast imaging quality1,2

 

Optimizing your DEFINTY® contrast images...

Images are for illustrative purposes only.
*Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension

Lantheus Medical Imaging, Inc., is pleased to provide these suggestions for optimizing DEFINITY® images in your patients with suboptimal echocardiograms. For more information, please contact your Lantheus sales representative.


References

1. Mulvagh SL, Rakowski H, Vannan MA, et al. American Society of Echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography. J Am Soc Echocardiogr. 2008;21(11):1179-1201.
2. Mulvagh SL, DeMaria AN, Feinstein SB, et al. Contrast echocardiography: current and future applications. J Am Soc Echocardiogr. 2000;13(4):331-342.
3.The Complete 2010 ICAEL Standards for Accreditation in Adult Echocardiography Testing: Parts I Through IV. Intersocietal Commission for the Accreditation of Echocardiography Laboratories Web site. http://www.icael.org/icael/standards/ICAEL_2010_Standards_%20(Adult%20Echo).pdf. Published June 2010. Accessed July 23, 2012.
4. Witt SA, McCulloch M, Sisk E, et al. Achieving a diagnostic contrast-enhanced echocardiogram: a series on contrast echocardiography, article 4. J Am Soc Echocardiogr. 2001;14(4):327-334.
5. Burgess P, Moore V, Bednarz J, et al. Performing an echocardiographic examination with a contrast agent: a series on contrast echocardiography, article 2. J Am Soc Echocardiogr. 2000;13(6):629-636.
6.Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinicalmanagement in a large prospective cohort. J Am Coll Cardiol. 2009;53(9):802-810.
7. Kitzman DW, Goldman ME, Gillam LD, Cohen JL, Aurigemma GP, Gottdiener JS. Efficacy and safety of the novel ultrasound contrast agent perflutren (Definity) in patients with suboptimal baseline left ventricular echocardiographic images. Am J Cardiol. 2000;86(6):669-674.
8. DEFINITY® US Package Insert.


INDICATIONS

Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

CONTRAINDICATIONS

Do not administer DEFINITY® to patients with known or suspected hypersensitivity to perflutren.

IMPORTANT SAFETY INFORMATION

WARNING:  Serious Cardiopulmonary Reactions

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration.

  • Assess all patients for the presence of any condition that precludes DEFINITY® administration [see Contraindications (4)].

  • Always have resuscitation equipment and trained personnel readily available.


In postmarketing use, rare but serious cardiopulmonary or hypersensitivity reactions have been reported during or shortly following perflutren-containing microsphere administration [see Adverse Reactions (6)]. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions [see Adverse Reactions (6.2)]. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.

Please see full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions.

Lantheus Medical Imaging, Inc.
HOME Order